Veru (VERU) Operating Income (2012 - 2024)
Veru (VERU) posted quarterly Operating Income of $1.6 million for Q4 2024, up 120.1% year-over-year from $719721.8 in Q1 2024, and up 119.31% quarter-over-quarter from -$8.2 million in Q3 2024.
Veru (VERU) Operating Income (2012 - 2024) Analysis & Trends
Veru (VERU) has reported Operating Income for 13 consecutive years, with $1.6 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Operating Income rose 120.1% year-over-year to $1.6 million; the TTM figure through Sep 2025 stood at $1.6 million (up 104.29% YoY), while the FY2025 annual figure was $1.6 million, up 104.29% from the prior year.
- Operating Income rose to $1.6 million in Q4 2024 per VERU's latest filing, from -$8.2 million in the prior quarter.
- Across five years, Operating Income topped out at $19.2 million in Q4 2020 and bottomed at -$44.9 million in Q3 2022.
- Historically, Operating Income has averaged -$10.6 million across 5 years, with a median of -$8.2 million in 2023.
- Annual changes were most pronounced in 2020 — Operating Income jumped 1175.28% — and 2022, when it plunged 2301.48%.
- Veru's Operating Income stood at $19.2 million in 2020, then tumbled by 125.86% to -$5.0 million in 2021, then plunged by 654.79% to -$37.5 million in 2022, then surged by 78.95% to -$7.9 million in 2023, then jumped by 120.1% to $1.6 million in 2024.
- Business Quant data shows VERU's Operating Income at $1.6 million in Q4 2024, -$8.2 million in Q3 2024, and -$10.9 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Veru | 59.70 Mn | 33.91 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.58 Mn |
| Sep 30, 2024 | -8.21 Mn |
| Jun 30, 2024 | -10.94 Mn |
| Mar 31, 2024 | -9.89 Mn |
| Dec 31, 2023 | -7.88 Mn |
| Sep 30, 2023 | -8.18 Mn |
| Jun 30, 2023 | -13.74 Mn |
| Mar 31, 2023 | -34.41 Mn |
| Dec 31, 2022 | -37.45 Mn |
| Sep 30, 2022 | -44.94 Mn |
| Jun 30, 2022 | -21.82 Mn |
| Mar 31, 2022 | -11.76 Mn |
| Dec 31, 2021 | -4.96 Mn |
| Sep 30, 2021 | -1.87 Mn |
| Jun 30, 2021 | -2.87 Mn |
| Mar 31, 2021 | -1.47 Mn |
| Dec 31, 2020 | 19.19 Mn |
| Sep 30, 2020 | -11.27 Mn |
| Jun 30, 2020 | -1.39 Mn |
| Mar 31, 2020 | -299,678.00 |